Challenges and solutions of immunization safety surveillance in Assosa Zone, Ethiopia: Mixed methods
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Background: Adverse Events Following Immunizations (AEFIs) reporting has increased over the past sixteen years worldwide, and requires strengthening in majority of Low Middle-Income Countries (LMICs) including Ethiopia. Additional efforts are needed to ensure and improve data quality, AEFI reporting and surveillance of immunisation safety in every country. Immunisation Safety Surveillance (ISS) is vital to identify AEFIs.
Objective: to assess challenges and solutions of immunisation safety surveillance in Assosa zone, Ethiopia,
Methods: Health facility based parallel convergent quantitative and qualitative data collected from 300 and nine respondents respectively.
Result: Only 14 (4.7%) respondents had ever reported AEFI case to a higher level and 69 (23%) ever treated it. All the zone and woreda level experts mentioned the performance related immunization safety surveillance is very minimal. The major challenges stated by respondents were; in-availability or denial of AEFI case presence (60%), no clarity on how to do immunisation safety surveillance (22%), no standard reporting forms (20.7%), thinking AEFI is mild problem which could resolve by itself or care takers could manage it at home (14.6%), there is no road and electricity access (9.3%), and health care providers has the ability to treat the case at health facility level (8.3%). Similarly, the in-depth interview participants mentioned that the performance related to immunisation safety surveillance was minimal due to poor infrastructure, lack of adequate information about AEFI, absence of proper AEFI reporting system; no training for AEFI, community members are not informed to report AEFI and experience of home treatment for mild cases. A total of 40 possible solutions to improve AEFI surveillance were proposed from one time to 185 times. The first five top solutions were; Providing training for health care workers (185), Sharing information or Create Awareness (129), Provide training for Health Development Armies or involve HDAs (100), Strengthening supervision (76), and Avail supplies (drugs, manpower, kits) for AEFI reporting (75)
Conclusion: the major obstacles for immunization safety surveillance were; lack of clarity on how to report, lack of attention from higher bodies, lack of ownership for the work and unavailability of reporting formats. The responsible bodies need to solve the existing challenges in line with the proposed solutions.
##plugins.themes.bootstrap3.displayStats.downloads##
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This open-access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
You are free to: Share — copy and redistribute the material in any medium or format. Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
How to Cite
References
Reference
Agarwal, R, Daher, AM & Ismail, N. 2013. Knowledge, practices and attitudes towards adverse drug reaction reporting by private practitioners from Klang valley in Malaysia. Malaysian Journal of Medical Sciences 20(2):52–62.
Ali, M, Rath, B & Thiem, VD. 2015. Vaccine safety monitoring systems in developing countries: An example of the Vietnam Model. Current Drug Safety 10(1):60–67.
Bok, K. 2014. Overview of the US vaccine safety surveillance systems and ongoing scientific activities to monitor maternal vaccine safety overview. National vaccine programme office. USA: Department of Health and Human Services.
Cambridge English Dictionary. 2020. Sv “challenge’”. Cambridgeshire: Cambridge.
Constantine, M, Cremance, T, Juru, T, Gerald, S, Notion, TG, Peter, N & Mufuta, T. 2018. Surveillance system in Guruve district, Mashonaland Central 2017. Postgraduate Medical Journal 31(202):1–10.
Creswell, JW. 2018. Research design: quantitative, qualitative and mixed methods approach. 5th edition. London: Sage.
FMOH Ethiopia. 2015. Ethiopia national expanded programme on immunisation comprehensive plan 2016 – 2020. Addis Ababa: FMOH.
Funmilola, OO. 2015. Knowledge management as an important tool in organisational management: a review of literature. Library Philosophy and Practice (e-journal):1–24.
Gattás, VL, Braga, PE, Koike, ME, Lucchesi, MB, Oliveira, MM, Piorelli, RO, Queiroz, V & Precioso, AB. 2018. Safety Assessment of seasonal trivalent influenza Vaccine produced by Instituto Butantan from 2013 to 2017. Journal of the Sauopolo Institute of Tropical Medicine 61(e4):1–8.
Graham, JE, Rodriguez, AB, Huzair, F & Zinck, E. 2012. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Elsevier 30(33):4953–4959.
Gidudu, J, Shaum, A, Dodoo, A, Bosomprah, S, Bonsu, G, Amponsa-Achiano, K, Darko, D, Sabblah, G, Opare, J, Nyaku, M, Owusu-Boakye, B, Oduro, A, Aborigo, R, Conklin, L, Welaga, P & Ampadu, H. 2020. Barriers to healthcare workers reporting adverse events following immunisation in four regions of Ghana. Vaccine 38(5):1009-1014.
Griffin, MR, Braun, MM & Bart, KJ. 2009. What should an ideal vaccine post licensure safety system be? American Journal of Public Health 99(2):s345–s350.
Gupta, SK, Nayak, RP, Shivaranjani, R & Vidyarthi, SK. 2015. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspectives in Clinical Research 6(1):45–52.
Israel, GD. 2013. Determining sample size. Institute of Food and Agricultural Sciences (IFAS), University of Florida, PEOD-6:1–5.
Lei, J, Balakrishnan, MR, Gidudu, JF & Zuber, PLF. 2018. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunisation reporting 2000-2015. Elsevier 36(12):1577–1582.
Masuka, JT & Khoza, S. 2019. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programmeme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase from 1997 to 2017. BioMedCentral Public Health 19 (1166):1-11.
Ogunyemi, RA & Odusanya, OO. 2016. A survey of knowledge and reporting practices of primary healthcare workers on adverse experiences following immunisation in Alimosho Local Government Area, Lagos. Nigerian Postgraduate Medical Journal 23(2):79–85.
Pangil, F & Nassrudin, AM. 2013. Knowledge and the importance of knowledge sharing in organisations. University Utara Malaysia:49–361.
Parrella, A. 2014. Post marketing vaccine safety passive surveillance: an exploratory study of parent and healthcare provider reporting of Adverse Events following Immunisation (AEFI). D Phil Medicine Thesis. Australia: Adelaide.
Saxena, A. 2015. Research ethics. Geneva: WHO.
Sebastian, J, Gurumurthy, P, Ravi, MD & Ramesh, M. 2019. Active surveillance of adverse events following immunisation (AEFI): a prospective 3-year vaccine safety study. Therapeutic Advances in Vaccines and Immunotherapy 7:1–9.
Singh, AK, Wagner, AL, Joshi, J, Carlson, BF, Aneja, S, & Boulton, ML. 2017. Application of the revised WHO causality assessment protocol for adverse events following immunisation in India. Vaccine 35(33):1–7.
Tew, MM, Teoh, BC, Baidi, ASM, & Saw, HL. 2016. Assessment of knowledge, attitude and practices of adverse drug reaction reporting among doctors and pharmacists in primary healthcare. Advances in Pharmacoepidemiology and Drug Safety 5(4):1–6.
WHO. 2016. Global Manual on surveillance of adverse events following immunisation. WHO publication. Geneva: WHO.
Worku, K. 2018. Correspondence. 5 February, Addis Ababa.